Assess whether biosimilarity is analytically justified (a4a1ce)

Situation

The desk packet is 505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate. Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate.

Hypotheses to test

• Authorize Proceed under protocol now; 505(b)(2) literature-to-product bridge table already has the discriminator after a payer demanding RWE the protocol cannot generate.
• Keep Pause the pathway in force until 505(b)(2) literature-to-product bridge table is completed after a payer demanding RWE the protocol cannot generate for pharmacovigilance medical reviewer.
• Treat 505(b)(2) literature-to-product bridge table as Escalate safety review because both readings appear after a payer demanding RWE the protocol cannot generate.
• Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the page biosimilarity is analytically justified turns on in 505(b)(2) literature-to-product bridge table.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a payer demanding RWE the protocol cannot generate and write the one fact that would move biosimilarity is analytically justified for pharmacovigilance medical reviewer.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a payer demanding RWE the protocol cannot generate, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.